US20090025359A1 - Process for creating spun yarn - Google Patents
Process for creating spun yarn Download PDFInfo
- Publication number
- US20090025359A1 US20090025359A1 US11/920,103 US92010306A US2009025359A1 US 20090025359 A1 US20090025359 A1 US 20090025359A1 US 92010306 A US92010306 A US 92010306A US 2009025359 A1 US2009025359 A1 US 2009025359A1
- Authority
- US
- United States
- Prior art keywords
- fibers
- silver
- copper
- input
- metallized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 42
- 230000008569 process Effects 0.000 title description 8
- 239000000835 fiber Substances 0.000 claims abstract description 185
- 229910052709 silver Inorganic materials 0.000 claims abstract description 69
- 239000004332 silver Substances 0.000 claims abstract description 69
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229910052802 copper Inorganic materials 0.000 claims abstract description 30
- 239000010949 copper Substances 0.000 claims abstract description 30
- 239000004753 textile Substances 0.000 claims abstract description 30
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 239000011248 coating agent Substances 0.000 claims abstract description 12
- 238000000576 coating method Methods 0.000 claims abstract description 12
- 239000002184 metal Substances 0.000 claims abstract description 6
- 229910052751 metal Inorganic materials 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000011159 matrix material Substances 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 16
- 238000009960 carding Methods 0.000 claims description 14
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- -1 antifungals Substances 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 238000004080 punching Methods 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 238000009987 spinning Methods 0.000 claims description 2
- 229920002972 Acrylic fiber Polymers 0.000 claims 2
- 229920003043 Cellulose fiber Polymers 0.000 claims 2
- 230000029663 wound healing Effects 0.000 abstract description 11
- 229910021645 metal ion Inorganic materials 0.000 abstract description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 50
- 208000027418 Wounds and injury Diseases 0.000 description 33
- 206010052428 Wound Diseases 0.000 description 32
- 239000000047 product Substances 0.000 description 27
- 241000894006 Bacteria Species 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000000843 anti-fungal effect Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000002109 Argyria Diseases 0.000 description 3
- 241001554566 Argyria Species 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000019645 odor Nutrition 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229940050561 matrix product Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000003378 silver Chemical class 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 244000062175 Fittonia argyroneura Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/83—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with metals; with metal-generating compounds, e.g. metal carbonyls; Reduction of metal compounds on textiles
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4209—Inorganic fibres
- D04H1/4234—Metal fibres
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4382—Stretched reticular film fibres; Composite fibres; Mixed fibres; Ultrafine fibres; Fibres for artificial leather
- D04H1/43825—Composite fibres
- D04H1/43828—Composite fibres sheath-core
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4382—Stretched reticular film fibres; Composite fibres; Mixed fibres; Ultrafine fibres; Fibres for artificial leather
- D04H1/43835—Mixed fibres, e.g. at least two chemically different fibres or fibre blends
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/74—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being orientated, e.g. in parallel (anisotropic fleeces)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2904—Staple length fiber
- Y10T428/2907—Staple length fiber with coating or impregnation
Definitions
- the present invention relates to an antimicrobial, absorbent yarn textile matrix fostering a moist wound-healing environment which minimizes or eliminates the possibility of infection, and is especially useful as a component of a wound dressing.
- Silver is also known to exhibit wound-healing properties. Expeditious wound healing benefits the patient by providing increased comfort and decreased susceptibility to further infection and secondary injury. There is a current need for wound care products that utilize silver to increase the rate of wound healing.
- silver creams including silver sulfadiazine
- the dressing must be removed for reapplication of the cream.
- a wound care product that releases silver ions over an extended period of time and which alleviates the need for frequent removal or replacement of the dressing or application of silver creams.
- Silver wound care products that use too much silver would be unduly expensive and wasteful.
- silver wound care products that use too little silver would be ineffective.
- MMPs matrix metalloproteinases
- Excessive MMPs are known to interfere with and slow the wound healing process.
- Existing silver-based wound care products inhibit MMPs too much, and also interfere with the wound healing process.
- the present invention may also be embodied as a method of manufacturing textile components from an input fiber having improved anti-microbial properties comprising the steps of:
- FIG. 1 is a flowchart showing one embodiment of a process for creating textile components according to the present invention.
- One embodiment of the present invention is a novel antibiotic textile matrix made of a metallized yarn having absorptive properties that are especially useful in wound care products, such as wound dressings.
- the textile matrix of the invention includes silver coated fibers.
- the silver coated fibers may be manufactured as described in U.S. Pat. No. 4,042,737, entitled “Process For Producing Crimped Metal-Coated Filamentary Materials, And Yarns And Fabrics Obtained Therefrom,” issued to Rohm and Haas Company (Philadelphia, Pa.), on Aug. 16, 1977, hereby incorporated by reference as if set forth in its entirety herein. Similar fibers are commercially available from Noble Fiber Technologies sold under the tradename X-static®.
- Copper has been known and proven to be a very effective anti-fungal agent and also has other anti-microbial properties. It is also very ductile and can be used to metallize a surface of a textile substrate. The combination of silver with copper is very effective in providing not only anti-bacterial, but also anti-fungal properties.
- Silver-coated fibers such as the X-Static® product, can be copper coated using conventional electrodeless copper chemistry. Zinc-coated fibers can also be incorporated into the textile matrix.
- the addition of the metallized fibers also reduce physical adherence of the dressing to the wound site.
- This reduced physical adherence reduces the amount that a wound dressing sticks to, and pulls on the wound and making the dressing more comfortable to wear.
- the reduced adherence also decreases pain and discomfort when the dressing is removed or replaced.
- the preferred substrate of the silver-coated fiber is nylon.
- the following table describes the preferred characteristics of the metallized fibers:
- the textile matrix of the present invention is spun yarn using fibers of the length, denier per fiber and silver to copper ratio as specified in the table above.
- the desirable antimicrobial properties and efficacy of the textile matrix are determined using the Dow Corning Shake Flask Test over 24 hours of the New NY State 63 Test for Bacteriostatic Activity. Other tests included, but are not limited to ASTM E-2149 for a time period ranging from 10 minutes to 7 days.
- the kill rate is not less than about 70%. More preferably the kill rate is not less than about 85%, and ideally the kill rate is not less than about 95%.
- the present invention can also be used for other applications such as being woven into material for odor prevention, socks for athlete's foot prevention and into bedding liners to kill dust mites, etc.
- Manufacturing the textile matrix involves preparing the input fiber, carding the fiber (includes sub-steps: opening the silver-coated fiber, blending and orienting the fiber, cross-lapping the fiber) and optionally, needle punching the web.
- Manufacturing a sliver involves preparing the input fiber, carding the fiber (includes sub-steps: opening the silver-coated fiber, blending and orienting the fiber, drawing the fiber) and optionally roving to further condense the fiber.
- FIG. 1 the steps of the manufacturing process according to one embodiment of the present invention are shown.
- step 110 the metal coated fiber is prepared.
- One such method is that described in U.S. Pat. No. 4,042,737, referenced above.
- the metallized fiber is preferably manufactured in the form of a continuous filament and then cut into short segments having lengths as described above.
- the inventors have surprisingly discovered that by using cut yarn, rather than staple fiber, the properties of the final product are dramatically improved.
- the fibers are significantly easier to metallize in the manufacturing process because there is less clumping (adhesion to itself) of fibers. The inventors believe that this improvement is facilitated by the general axial alignment of the fibers after they are cut, relative to the random orientation of the fibers that result from coating staple product.
- Another factor that helps prevent clumping is the manufacture of the short fibers from long fibers after aqueous processing, as opposed to processing short (staple) fibers and allowing them to dry together.
- Copper-coated yarn is prepared by using commercially available copper chemistry applied to silver-coated fibers.
- step 120 carding is accomplished using a traditional carding process.
- a preferred carding machine is the Bematic card, manufactured by Bettarinj & Serafirij Sarl. (Prato, Italy).
- Carding blends the fibers together and orients them in generally the same direction, i.e., generally parallel. Carding includes the following sub-steps:
- the metallized fibers are opened.
- the silver-coated fiber is processed wet and subsequently dried, it clumps together (though not to the same extent as staple fiber that is processed and then dried).
- the fiber is opened, to separate the individual staple fibers from each other to enable it to be blended with the alginate.
- the silver-coated fiber and the absorbent fiber are then blended in step 123 and oriented in step 127 to create a web.
- the blended fibers may be opened in step 125 .
- step 129 the output of above steps is drawn to create a sliver having absorbent and antimicrobial properties.
- the sliver may optionally be put through a roving process in step 140 .
- step 150 the manufactured sliver is spun onto a bobbin to be knit, woven, etc. in a traditional textile operation.
- step of cross-lapping the fiber, step 128 and needle punching the web, step 130 may be employed as is known in the prior art to result in a textile matrix.
- the percentage of metallized fiber, such as the X-Static® product used in the textiles typically range from 2% to 25% by weight, but overall from 1% to 75% of the spun yarn by weight.
- the matrix was tested for antimicrobial activity and absorbance using the NY State 63 Test for Bacteriostatic Activity. Five (5) 1′′ inch squares of the textile matrix were used as samples.
- the jar was shaken vigorously for about 1 minute. Serial dilutions were made and placed on AATCC bacteriostasis agar. Plates containing the agar were then incubated for 24-48 hours at 37° C. The percentage reduction of inoculum by samples and controls was calculated.
- the textile matrix may include additional fibers other than the silver-coated fibers and absorptive fibers.
- additional fibers include cotton, cellulose, polyester, acrylic and nylon.
- the textile matrix of the invention may also include other antibiotics, such as doxycycline or other topical antibiotics.
- the textile matrix may also include hormone treatments, such as estrogen, to facilitate wound healing.
- antibiotics and hormones may be used in conjunction with the textile matrix as described in U.S. Pat. No. 5,914,124.
- the textile matrix may also include fibers, particles or similar substrates coated with antibiotic (e.g., anti-microbial, anti-bacterial, and/or anti-fungal) metals, such as copper and/or zinc.
- antibiotic e.g., anti-microbial, anti-bacterial, and/or anti-fungal
- a preferred combination textile matrix product includes silver-coated fibers and copper-coated fibers.
- Another preferred combination textile matrix product includes silver-coated fibers and zinc-coated fibers.
Landscapes
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Materials For Medical Uses (AREA)
- Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
Abstract
Description
- This application is related to, and claims priority from U.S. patent application Ser. No. 10/938,868 “Process for Creating Spun Yarn” filed May 10, 2005, and hereby incorporates by reference this application as set forth in its entirety herein.
- The present invention relates to an antimicrobial, absorbent yarn textile matrix fostering a moist wound-healing environment which minimizes or eliminates the possibility of infection, and is especially useful as a component of a wound dressing.
- Silver has been used as an antimicrobial since ancient times. It has been used to stop bacterial infections. Recent years have seen a renewed interest in silver. This renewed interest is driven in part by the development of antibiotic resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA). Conventional antibiotics have little or no effect on these resistant bacteria. Resistant bacteria are especially problematic in wounds, causing infections, destroying tissue, delaying the healing process and causing unpleasant odors. Silver is a broad-spectrum antibiotic that is effective against such resistant bacteria. Even though these bacteria develop resistance to antibiotics, they do not develop resistance to silver. There is a current need for an antibiotic wound care product that uses silver to treat and/or prevent MRSA and other infections caused by resistant bacteria.
- Silver is also known to exhibit wound-healing properties. Expeditious wound healing benefits the patient by providing increased comfort and decreased susceptibility to further infection and secondary injury. There is a current need for wound care products that utilize silver to increase the rate of wound healing.
- Many presently existing antimicrobial wound care products have been used to treat infections, however, these lose their effectiveness in a short period of time. This is especially true for wound care products that contain silver in an ionic form. Ionic silver is readily dissolved in an aqueous environment and dissipated. Such dressings must be replaced frequently often resulting in extreme pain or discomfort and inconvenience for the patient as the dressing is removed and a new dressing is applied.
- Similarly, silver creams (including silver sulfadiazine) must be consistently reapplied to the injured area, and the dressing must be removed for reapplication of the cream. There is currently a need for a wound care product that releases silver ions over an extended period of time and which alleviates the need for frequent removal or replacement of the dressing or application of silver creams.
- Silver may be commonly applied in ionic form as a silver salt. Such salts can be irritating to the skin. Moreover, prolonged contact with silver salts can cause argyria, which is characterized by a pronounced, permanent ashen-gray skin discoloration, which can be localized or universal. There currently is a need for a non-irritating silver wound care product that does not rely on silver salts for the delivery of silver ions. There is also a current need for an ionic silver wound care product that does not cause argyria.
- Metallic silver is a costly substance. Silver wound care products that use too much silver would be unduly expensive and wasteful. On the other hand, silver wound care products that use too little silver would be ineffective. There currently is a need for a silver wound care product that enables the delivery of an optimal dosage of silver to the wound area.
- Silver is known to affect the operation of matrix metalloproteinases (MMPs). Excessive MMPs are known to interfere with and slow the wound healing process. Existing silver-based wound care products inhibit MMPs too much, and also interfere with the wound healing process. There is currently a need for a silver wound care product that delivers a proper amount of silver, which limits the activity of MMPs without unduly restricting MMPs activity.
- Other existing silver-based wound care products are made from silver-plated films with limited flexibility. These dramatically reduce the flexibility and comfort of the bandages. Textile bandages are much more flexible and hence, much more comfortable for patients. There is currently a need for a silver-based wound care product that is more flexible and comfortable.
-
- The present invention may be embodied as a method of manufacturing a textile matrix having improved anti-microbial properties comprising the steps of:
- a) preparing input fibers [110], the preparation includes the following substeps:
- i. providing input fibers [113] with a predetermined length range, and
- ii. metallizing the input fibers [115];
- b) carding the metallized fibers [120] by the following sub-steps:
- i. opening the metallized fibers [121] to separate the individual fibers from each other,
- ii. blending the metallized fibers [123] with other fibers,
- iii. orienting the blended fibers [127] in generally the same direction to create a web, and
- iv. cross-lapping the fibers [128] of the web.
- a) preparing input fibers [110], the preparation includes the following substeps:
- The present invention may also be embodied as a method of manufacturing textile components from an input fiber having improved anti-microbial properties comprising the steps of:
-
- a) preparing input fibers [110], the preparation includes the following substeps:
- i. providing input fibers [113] with a predetermined length range, and
- ii. metallizing the input fibers [115];
- b) carding the metallized fibers [120] by the following sub-steps:
- i. opening the metallized fibers [121] to separate the individual fibers from each other,
- ii. blending the metallized fibers [123] with other fibers,
- iii. orienting the blended fibers [127] in generally the same direction to create a web, and
- iv. drawing the web [129] to create a sliver having fibers with antimicrobial properties.
- a) preparing input fibers [110], the preparation includes the following substeps:
- It is another object of the present invention to provide a wound care product which employs silver metallized yarn capable of releasing ionic silver to inhibit infections and facilitate wound healing.
- It is another object of the present invention to provide a wound care product which is capable of releasing ionic silver, copper and zinc ions over an extended period of time without the use of irritating metal salts.
- It is another object of the present invention to provide a wound care product which is capable of releasing ionic silver which does not cause argyria.
- It is another object of the present invention to provide a wound care product which maintains a moist wound-healing environment while preventing the growth of bacteria and fungi.
- It is another object of the present invention to provide a wound care product which retains a moist wound environment, but eliminates unpleasant odors.
- It is another object of the present invention to provide an anti-bacterial, and anti-fungal metallized yarn which employs a large surface area for discharge of metal ions.
- It is another object of the present invention to provide an anti-bacterial, and anti-fungal metallized yarn in which the metal ions do not become detached from the yarn substrate.
- It is another object of the present invention to provide a wound care product which enables the delivery of an optimal dosage of silver ion.
- It is another object of the present invention to provide a wound care product which delivers a predetermined rate of silver release, which limits MMP activity to a level roughly associated with optimum wound healing.
- It is another object of the present invention to provide an anti-bacterial, and anti-fungal metallized yarn which can be used in applications including hosiery and other knit-wear.
- It is another object of the present invention to provide an anti-bacterial, and anti-fungal metallized yarn which is easy and inexpensive to manufacture.
- It is another object of the present invention to provide a combination of silver metallized and copper metallized yarn to create wound care products which treat and/or prevent resistant bacterial infections such as MRSA and fungal infections.
- A complete understanding of the present invention may be obtained by reference to the accompanying drawing, when considered in conjunction with the subsequent detailed description, in which:
-
FIG. 1 is a flowchart showing one embodiment of a process for creating textile components according to the present invention. - One embodiment of the present invention is a novel antibiotic textile matrix made of a metallized yarn having absorptive properties that are especially useful in wound care products, such as wound dressings.
- The textile matrix of the invention includes silver coated fibers. The silver coated fibers may be manufactured as described in U.S. Pat. No. 4,042,737, entitled “Process For Producing Crimped Metal-Coated Filamentary Materials, And Yarns And Fabrics Obtained Therefrom,” issued to Rohm and Haas Company (Philadelphia, Pa.), on Aug. 16, 1977, hereby incorporated by reference as if set forth in its entirety herein. Similar fibers are commercially available from Noble Fiber Technologies sold under the tradename X-static®.
- Copper has been known and proven to be a very effective anti-fungal agent and also has other anti-microbial properties. It is also very ductile and can be used to metallize a surface of a textile substrate. The combination of silver with copper is very effective in providing not only anti-bacterial, but also anti-fungal properties.
- Silver-coated fibers, such as the X-Static® product, can be copper coated using conventional electrodeless copper chemistry. Zinc-coated fibers can also be incorporated into the textile matrix.
- In addition to providing an antimicrobial effect, the addition of the metallized fibers also reduce physical adherence of the dressing to the wound site.
- This reduced physical adherence reduces the amount that a wound dressing sticks to, and pulls on the wound and making the dressing more comfortable to wear. The reduced adherence also decreases pain and discomfort when the dressing is removed or replaced.
- The preferred substrate of the silver-coated fiber is nylon. The following table describes the preferred characteristics of the metallized fibers:
-
Length Denier (cm) (dpf) Silver/Copper (% w/w) Outside range ½-8 0.5-50 3%-75% Intermediate range ¼-6 0.7-30 9%-60% Optimal range 1-3 1-10 12%-30% Ideal ~2 ~3 ~21 - Using fibers having the length, denier per fiber and silver to copper ratio, the optimum ion release is obtained to prevent infections and optimizes healing.
- The textile matrix of the present invention is spun yarn using fibers of the length, denier per fiber and silver to copper ratio as specified in the table above.
- The desirable antimicrobial properties and efficacy of the textile matrix are determined using the Dow Corning Shake Flask Test over 24 hours of the New NY State 63 Test for Bacteriostatic Activity. Other tests included, but are not limited to ASTM E-2149 for a time period ranging from 10 minutes to 7 days. Preferably the kill rate is not less than about 70%. More preferably the kill rate is not less than about 85%, and ideally the kill rate is not less than about 95%.
- The present invention can also be used for other applications such as being woven into material for odor prevention, socks for athlete's foot prevention and into bedding liners to kill dust mites, etc.
- Manufacturing the textile matrix involves preparing the input fiber, carding the fiber (includes sub-steps: opening the silver-coated fiber, blending and orienting the fiber, cross-lapping the fiber) and optionally, needle punching the web.
- Manufacturing a sliver involves preparing the input fiber, carding the fiber (includes sub-steps: opening the silver-coated fiber, blending and orienting the fiber, drawing the fiber) and optionally roving to further condense the fiber.
- Each of these steps is described in the ensuing text.
- Referring now to
FIG. 1 , the steps of the manufacturing process according to one embodiment of the present invention are shown. - In
step 110, the metal coated fiber is prepared. One such method is that described in U.S. Pat. No. 4,042,737, referenced above. - In step 113, the metallized fiber is preferably manufactured in the form of a continuous filament and then cut into short segments having lengths as described above. The inventors have surprisingly discovered that by using cut yarn, rather than staple fiber, the properties of the final product are dramatically improved. In
step 115 the fibers are significantly easier to metallize in the manufacturing process because there is less clumping (adhesion to itself) of fibers. The inventors believe that this improvement is facilitated by the general axial alignment of the fibers after they are cut, relative to the random orientation of the fibers that result from coating staple product. Another factor that helps prevent clumping is the manufacture of the short fibers from long fibers after aqueous processing, as opposed to processing short (staple) fibers and allowing them to dry together. - Copper-coated yarn is prepared by using commercially available copper chemistry applied to silver-coated fibers.
- In
step 120, carding is accomplished using a traditional carding process. A preferred carding machine is the Bematic card, manufactured by Bettarinj & Serafirij Sarl. (Prato, Italy). - Carding blends the fibers together and orients them in generally the same direction, i.e., generally parallel. Carding includes the following sub-steps:
- 2a. Opening the Silver-Coated Fiber with or without Copper-Coated Fibers
- In
step 121, the metallized fibers are opened. When the silver-coated fiber is processed wet and subsequently dried, it clumps together (though not to the same extent as staple fiber that is processed and then dried). The fiber is opened, to separate the individual staple fibers from each other to enable it to be blended with the alginate. - 2b. Blending and Orienting the Fibers
- The silver-coated fiber and the absorbent fiber are then blended in
step 123 and oriented instep 127 to create a web. - Optionally, the blended fibers may be opened in
step 125. - 2c. Drawing the Fiber
- In
step 129, the output of above steps is drawn to create a sliver having absorbent and antimicrobial properties. - To further condense the fiber, the sliver may optionally be put through a roving process in
step 140. - In
step 150 the manufactured sliver is spun onto a bobbin to be knit, woven, etc. in a traditional textile operation. - Optionally, the step of cross-lapping the fiber,
step 128 and needle punching the web,step 130 may be employed as is known in the prior art to result in a textile matrix. - The end result will result in textile components used in making clothing and wound care products with optimum metal ion release and superior anti-odor, anti-static, anti-microbial, hydrodynamic, thermodynamic properties.
- The percentage of metallized fiber, such as the X-Static® product used in the textiles typically range from 2% to 25% by weight, but overall from 1% to 75% of the spun yarn by weight.
- Three textile matrix samples were manufactured according to the foregoing procedure with varying amounts of silver thread and cotton blend (10/90, and 50/50).
- The matrix was tested for antimicrobial activity and absorbance using the NY State 63 Test for Bacteriostatic Activity. Five (5) 1″ inch squares of the textile matrix were used as samples.
- Ten bottom sections of 35×10 mm disposable tissue culture dishes were placed in standard petri dishes containing 10 ml of sterile distilled water. 0.2 μl of a 24 hour broth culture containing 105 organisms was placed in the center of each disposable tissue culture dish. The test and control squares were then placed in the disposable tissue culture dishes, with one side in contact with the inoculum. The covers were than rep laced on the standard petri dishes. The petri dishes were then placed on a level shelf of an incubator at 37° C. and incubated for 24 hours. After 24 hours, the samples were removed from the petri dishes by means of a flamed forceps and placed into 100 ml of Letheen broth in an 8 oz. wide mouth jar. The jar was shaken vigorously for about 1 minute. Serial dilutions were made and placed on AATCC bacteriostasis agar. Plates containing the agar were then incubated for 24-48 hours at 37° C. The percentage reduction of inoculum by samples and controls was calculated.
-
Antimicrobial Activity % Silver % Cotton Kill Rate 10 90 >99.9% 50 50 >99.9% - As descried in more detail below, the textile matrix may include additional fibers other than the silver-coated fibers and absorptive fibers. Examples include cotton, cellulose, polyester, acrylic and nylon.
- The textile matrix of the invention may also include other antibiotics, such as doxycycline or other topical antibiotics. The textile matrix may also include hormone treatments, such as estrogen, to facilitate wound healing. For example, antibiotics and hormones may be used in conjunction with the textile matrix as described in U.S. Pat. No. 5,914,124.
- The textile matrix may also include fibers, particles or similar substrates coated with antibiotic (e.g., anti-microbial, anti-bacterial, and/or anti-fungal) metals, such as copper and/or zinc. A preferred combination textile matrix product includes silver-coated fibers and copper-coated fibers.
- Another preferred combination textile matrix product includes silver-coated fibers and zinc-coated fibers.
- While several presently preferred embodiments of the novel invention have been described in detail herein, many modifications and variations will now become apparent to those skilled in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and variations as fall within the true spirit of the invention.
Claims (33)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/920,103 US20090025359A1 (en) | 2005-05-10 | 2006-05-08 | Process for creating spun yarn |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67954305P | 2005-05-10 | 2005-05-10 | |
| PCT/US2006/017547 WO2006121935A2 (en) | 2005-05-10 | 2006-05-08 | Process for creating spun yarn |
| US11/920,103 US20090025359A1 (en) | 2005-05-10 | 2006-05-08 | Process for creating spun yarn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20090025359A1 true US20090025359A1 (en) | 2009-01-29 |
Family
ID=37397161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/920,103 Abandoned US20090025359A1 (en) | 2005-05-10 | 2006-05-08 | Process for creating spun yarn |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20090025359A1 (en) |
| WO (1) | WO2006121935A2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9387125B1 (en) | 2016-01-26 | 2016-07-12 | Vive Wear Llc | Sock for treatment of foot and leg wounds, methods of use and manufacture |
| US10064273B2 (en) | 2015-10-20 | 2018-08-28 | MR Label Company | Antimicrobial copper sheet overlays and related methods for making and using |
| US10500102B2 (en) | 2012-01-10 | 2019-12-10 | Vive Wear Llc | Sock for treatment of foot and leg wounds, methods of use and manufacture |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202010014723U1 (en) | 2010-07-14 | 2011-11-10 | Gebr. Becker Gmbh | Textile microbial storage |
| EP3072533B1 (en) | 2011-09-26 | 2019-11-06 | BSN medical GmbH | Improved wound dressing |
| DE102012210051A1 (en) | 2012-06-14 | 2013-12-19 | Christian Lauke | Microbicidal storage |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2907678A (en) * | 1954-03-23 | 1959-10-06 | Heberlein Patent Corp | Process of producing metallizing effects on textiles |
| US2934066A (en) * | 1957-05-11 | 1960-04-26 | Lohmann Kg | Metallized bandaging material especially for the treatment of wounds |
| US3646749A (en) * | 1969-12-24 | 1972-03-07 | King Seeley Thermos Co | Machine-washable metallized fibrous article and method of making same |
| US3666550A (en) * | 1968-05-24 | 1972-05-30 | Teijin Ltd | Textile materials having durable antistatic properties |
| US3686019A (en) * | 1968-10-24 | 1972-08-22 | Asahi Kogyo Co Ltd | Process for the manufacture of fibrous mixtures having superior antistatic characteristics |
| US4042737A (en) * | 1973-11-14 | 1977-08-16 | Rohm And Haas Company | Process for producing crimped metal-coated filamentary materials, and yarns and fabrics obtained therefrom |
| US4933129A (en) * | 1988-07-25 | 1990-06-12 | Ultrafibre, Inc. | Process for producing nonwoven insulating webs |
| US6087549A (en) * | 1997-09-22 | 2000-07-11 | Argentum International | Multilayer laminate wound dressing |
| US6132866A (en) * | 1998-01-28 | 2000-10-17 | E. I. Du Pont De Nemours And Company | Yarn blend for friction applications |
| US20020034906A1 (en) * | 1996-05-02 | 2002-03-21 | Heinz Berbner | Flame-proof fabrics based on melamine resin fibers |
| US20030176827A1 (en) * | 2001-12-20 | 2003-09-18 | Nobel Fiber Technologies | Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same |
-
2006
- 2006-05-08 WO PCT/US2006/017547 patent/WO2006121935A2/en not_active Ceased
- 2006-05-08 US US11/920,103 patent/US20090025359A1/en not_active Abandoned
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2907678A (en) * | 1954-03-23 | 1959-10-06 | Heberlein Patent Corp | Process of producing metallizing effects on textiles |
| US2934066A (en) * | 1957-05-11 | 1960-04-26 | Lohmann Kg | Metallized bandaging material especially for the treatment of wounds |
| US3666550A (en) * | 1968-05-24 | 1972-05-30 | Teijin Ltd | Textile materials having durable antistatic properties |
| US3686019A (en) * | 1968-10-24 | 1972-08-22 | Asahi Kogyo Co Ltd | Process for the manufacture of fibrous mixtures having superior antistatic characteristics |
| US3646749A (en) * | 1969-12-24 | 1972-03-07 | King Seeley Thermos Co | Machine-washable metallized fibrous article and method of making same |
| US4042737A (en) * | 1973-11-14 | 1977-08-16 | Rohm And Haas Company | Process for producing crimped metal-coated filamentary materials, and yarns and fabrics obtained therefrom |
| US4933129A (en) * | 1988-07-25 | 1990-06-12 | Ultrafibre, Inc. | Process for producing nonwoven insulating webs |
| US20020034906A1 (en) * | 1996-05-02 | 2002-03-21 | Heinz Berbner | Flame-proof fabrics based on melamine resin fibers |
| US6087549A (en) * | 1997-09-22 | 2000-07-11 | Argentum International | Multilayer laminate wound dressing |
| US6132866A (en) * | 1998-01-28 | 2000-10-17 | E. I. Du Pont De Nemours And Company | Yarn blend for friction applications |
| US20030176827A1 (en) * | 2001-12-20 | 2003-09-18 | Nobel Fiber Technologies | Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10500102B2 (en) | 2012-01-10 | 2019-12-10 | Vive Wear Llc | Sock for treatment of foot and leg wounds, methods of use and manufacture |
| US10064273B2 (en) | 2015-10-20 | 2018-08-28 | MR Label Company | Antimicrobial copper sheet overlays and related methods for making and using |
| US9387125B1 (en) | 2016-01-26 | 2016-07-12 | Vive Wear Llc | Sock for treatment of foot and leg wounds, methods of use and manufacture |
| US10639469B2 (en) | 2016-01-26 | 2020-05-05 | Vive Wear Llc | Sock for treatment of foot and leg wounds, methods of use and manufacture |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006121935A3 (en) | 2008-02-07 |
| WO2006121935A2 (en) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7385101B2 (en) | Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same | |
| US10667521B2 (en) | Antimicrobial material comprising synergistic combinations of metal oxides | |
| US8021685B2 (en) | Wound care device having fluid transfer properties | |
| US8921427B2 (en) | Antiseptic alginate preparation | |
| US20100003296A1 (en) | Manufacturing methods and applications of antimicrobial plant fibers having silver particles | |
| EP3860664B1 (en) | Wound dressing system | |
| CN101225604A (en) | Coated fabric containing antibiotic peptides and preparation method thereof | |
| US20090025359A1 (en) | Process for creating spun yarn | |
| US20040167483A1 (en) | Disposable diaper for combating diaper rash | |
| JP2000034640A (en) | Silver yarn interwoven body | |
| US9028530B2 (en) | Suture having antimicrobial properties | |
| US20080228123A1 (en) | Bandage with a hydrophilic foam containing silver and a hemastatic agent | |
| US20070122462A1 (en) | Bandage with a hydrophilic foam containing silver | |
| US11224227B2 (en) | Antimicrobial material comprising synergistic combinations of metal oxides | |
| JPH1037070A (en) | Antimicrobial fiber containing catechin of green tea component | |
| JP2014083070A (en) | Antibacterial and deodorant lower winding material for plaster | |
| HK1072733B (en) | Wound dressings comprising metallic silver | |
| Teot et al. | The management of wounds using Silvercel hydroalginate | |
| EP1594553A1 (en) | Disposable diaper for combating diaper rash | |
| Gray | Silvercel Non-Adherent dressing: Taking the pain out of antimicrobial use | |
| US11701261B2 (en) | Medical device containing a multi-ply knit fabric | |
| WO2002042549A2 (en) | Antimicrobially active underwear item and use of a textile for the production thereof | |
| KR200340586Y1 (en) | Nano sock which have feet smell and athlete's foot prevention function | |
| WO2021140331A1 (en) | Antimicrobial fibres |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: NOBLE BIO MATERIALS, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SATISH, CHANDRA N.;MCNALLY, WILLIAM F.;REEL/FRAME:020085/0096;SIGNING DATES FROM 20060505 TO 20070505 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
| AS | Assignment |
Owner name: JPMORGAN CHASE BANK, N.A., NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:NOBLE BIOMATERIALS, INC.;SAUQUOIT INDUSTRIES, LLC;NOBEL FIBER TECHNOLOGIES, LLC;REEL/FRAME:047211/0762 Effective date: 20181012 |
|
| AS | Assignment |
Owner name: NOBEL FIBER TECHNOLOGIES, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:057810/0044 Effective date: 20211012 Owner name: SAUQUOIT INDUSTRIES, LLC, PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:057810/0044 Effective date: 20211012 Owner name: NOBLE BIOMATERIALS, INC., PENNSYLVANIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:057810/0044 Effective date: 20211012 |